Elderly patients with locally advanced HNSCC treated with NBTXR3 activated by radiotherapy: a phase I trial

ESMO, Munich · 2018, Le Tourneau C. et al.


Le Tourneau C.1, Calugaru V.1, Moreno V.2, Mirabel X.3, Dodger B.2, Calvo E.2, Jouffroy T.1, Rodriguez J.1, Chilles A.1, Yemi M.1, Hoffmann C.1

1 – Medical Oncology, Institut Curie, Paris, FR
2 – Medical Oncology-Start Madrid-FJD, University Hospital “Fundacion Jimenez Diaz”, Madrid, ES
3 – Medical Oncology, Oscar Lambret Center, Lille, FR


Elderly patients (pts) with head and neck squamous cell carcinoma (HNSCC) represent 25% of the affected population. They are not always eligible to the same treatment of younger pts, thus require new therapies. NBTXR3, injectable hafnium oxide nanoparticles activated by radiotherapy (RT), was developed to increase the local deposit of energy within the tumor. It is currently evaluated in a phase I trial for locally advanced HNSCC in elderly and frail patients.

Current results indicate a safe and well tolerated profile for NBTXR3 even at the highest doses highlighting an encouraging perspective in the elderly. This population stress a medical need of which few HNSCC trials answer.

By continuing to use the site, you agree to the use of cookies.En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies. More information.En savoir plus.

The cookie settings on this website are set to “allow cookies” to give you the possibility to switch between languages in a way that this will not interfere with page navigation. If you continue to use this website without changing your cookie settings or you click “Accept” below then you are consenting to this.Par défaut, les paramètres de ce site autorisent les cookies pour vous permettre notamment de naviguer entre les différentes langues disponibles. Nous utilisons des cookies pour vous proposer un site internet facile d'utilisation, sécurisé et fonctionnel. Si vous les autorisez également, cliquez sur « Accepter » ou poursuivez simplement votre navigation.